A widely available antidepressant holds promise as a treatment for Covid-19, according to a new study. Covid-19 patients who received fluvoxamine were significantly less likely to require hospitalization than those who didn’t, in the largest clinical trial evaluating the antidepressant’s effect on Covid-19 to date. Fluvoxamine
POST TAGS:
antidepressantCOVID-19Daniel GriffinEdward MillsfluvoxamineMerck & Co. and Ridgeback Biotherapeutics LP’s experimental molnupiravir pillmonoclonal antibody treatmentsObsessive Compulsive DisorderOntarioprofessor of health sciences at McMaster University in Hamiltonserotonin reuptakeSSRIsthe National Institutes of Health and World Health OrganizationU.S. government